ProPhase Labs, Inc. (PRPH): Total Liabilities
$56.36M
As of 2025-12-31
$60.52M
As of 2026-06-30
+32.9%
3-year compound annual growth
+22.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $56.36M | +0.9% | 2026-06-01, Balance as of period end |
| 2024-12-31 | $55.85M | +31.3% | 2026-06-01, Balance as of period end |
| 2023-12-31 | $42.54M | +77.1% | 2025-04-01, Balance as of period end |
| 2022-12-31 | $24.02M | -21.7% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $30.67M | +47.1% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $20.85M | n/m | 2022-03-31, Balance as of period end |
| 2019-12-31 | $1.04M | -75.4% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $4.23M | n/a | 2020-03-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $56.36M | +0.9% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $8.26M | +15.7% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.66M | +20.0% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $4.57M | +106.0% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $2.27M | -34.4% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $70.10M | +362.3% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $968.0K | +8.2% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $62.07M | -5.7% |
Compare PRPH, CPHI, CRVO, ENSC side by side · Screen every company in Pharmaceutical Preparations ↗